Cepheid CPHD recently launched its Xpert MRSA NxG assay in the commercial markets overseas, after the test won the CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

Molecular diagnostic test company Cepheid stock dropped 12% today after reporting earnings last night. Is the move justified, or just market noise? So what: Cepheid reported revenue of $132.5 million ...

LONDON, Nov 15 (Reuters) - Global health advocates have written to the makers of a key mpox diagnostic test to call for its price to be cut from around $20 per test to $5, to help tackle low testing ...

SUNNYVALE, Calif., Feb. 10, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that Warren Kocmond, formerly Executive Vice President and Chief Operating Officer, has been promoted to the ...

Cepheid 's CPHD rapid influenza and RSV assay - the Xpert Flu+RSV Xpress test - recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.

Cepheid variable stars, pulsating stars with varying brightness and size, are crucial for determining astronomical distances, as exemplified by Edwin Hubble's Andromeda Galaxy measurement. The Leavitt ...